Quantitative Chest CT and Multi-Omics to Distinguish Asthma From COPD and Predict Treatment Response
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age19+
SponsorKorea University Guro Hospital
About this trial
This study aims to improve the diagnosis and treatment prediction of asthma and chronic obstructive pulmonary disease (COPD) by combining quantitative chest computed tomography (CT) imaging with multi-omics data.
Adults with asthma or COPD will be enrolled and undergo routine clinical evaluations, pulmonary function tests, blood tests, and chest CT scans. Additional samples, such as sputum and microbiome specimens, may also be collected. No experimental drugs or devices will be administered as part of this study.
Researchers will analyze CT imaging features together with clinical, laboratory, and biological data to better distinguish asthma from COPD and to identify factors that may predict treatment response. The findings are expected to contribute to more precise and personalized management of chronic airway diseases.
Eligibility criteria
Qualifiers
Age ≥19 years
COPD group: post-bronchodilator FEV1/FVC < 0.70
Asthma group: clinically confirmed diagnosis of asthma by a physician
Able to provide voluntary written informed consent
Disqualifiers
Acute exacerbation or active lower respiratory tract infection (e.g., pneumonia) within the past 4 weeks
Pregnancy or breastfeeding
Inability to undergo chest CT (e.g., poor cooperation or severe medical condition)
Refusal to consent to study procedures
Trial design
Treatments tested in this trial
- Not listed
Trial groups
200 Participants
are grouped into 1 trial groupSponsors and collaborators
Korea University Guro Hospital
Lead sponsor
The Korean Academy of Tuberculosis and Respiratory Diseases
Collaborator
Source ClinicalTrials.gov